95-05-6 Purity
95%+
If you have any other questions or need other size, please get a quote.
Specification
Recent studies have highlighted Irinotecan hydrochloride (IRI) potential when co-delivered with other agents to improve therapeutic outcomes. In particular, curcumin (CUR) has been explored as a sensitizer to enhance the efficacy of IRI. In a study examining co-delivery liposomes (CoIRI/CUR Lipo), CUR was shown to boost IRI's performance by promoting the conversion of IRI into its active metabolite, 7-ethyl-10-hydroxycamptothecin (SN-38), which plays a crucial role in inhibiting tumor cell proliferation. The CoIRI/CUR Lipo formulation not only delivered both drugs synergistically but also increased the tumor uptake, with CUR upregulating key enzymes like Carboxylesterase 2 (CSE 2) and Topoisomerase I (Top I) in cancer cells, enhancing the therapeutic impact. In vitro and in vivo evaluations demonstrated significant anticancer activity, with the liposomal formulation achieving a tumor inhibition rate of 94.43%. These findings emphasize the importance of combining Irinotecan hydrochloride with other bioactive compounds like curcumin for a more effective and targeted treatment strategy, showcasing its application in the development of advanced drug delivery systems for cancer therapy.
The molecular formula of Irinotecan hydrochloride is C33H39ClN4O6.
Some synonyms for Irinotecan hydrochloride include Irinotecan Hcl, Topotecin, CPT 11, Camptosar, and Campto.
The CAS number for Irinotecan hydrochloride is 100286-90-6.
Yes, Irinotecan hydrochloride is classified as an irritant.
The chemical structure of Irinotecan hydrochloride is shown in the provided images.
Yes, there is an anhydrous form of Irinotecan hydrochloride.
The WHO-DD name for Irinotecan hydrochloride is IRINOTECAN HYDROCHLORIDE.
Irinotecan hydrochloride is classified as a topoisomerase inhibitor.
The PubChem CID for Irinotecan hydrochloride is 11954009.
Irinotecan hydrochloride is classified as an irritant according to chemical safety guidelines.